An international study led by Université de Montréal scientists suggests that gene mutations may predispose some individuals to schizophrenia and provides new clues about the causes of this ambiguous disorder. Published today in the Proceedings of the National Academy of Sciences, the findings demonstrate that new mutations in the SHANK3 gene are found in schizophrenic patients.
"That these de novo or new mutations occur in schizophrenia is rather unexpected and may explain why the identification of the genes linked to this disease has been so difficult," says senior author Guy Rouleau, a Université de Montréal professor, director of the Sainte-Justine University Hospital Research Center and a scientist at the Research Centre of the Centre Hospitalier de l'Université de Montréal.
"Our findings show that a significant number of schizophrenia cases are the result of new genetic mutations in the SHANK3 gene. Where previous approaches have failed, our detailed analyses and rich patient database led us to this discovery. We are convinced that future studies will validate the SHANK3 gene as a marker for schizophrenia," continues Dr. Rouleau, who is Canada Research Chair in Genetics of the Nervous System.
Autism and schizophrenia link
"The SHANK3 gene has previously been linked to autism," adds lead author Julie Gauthier, a Université de Montréal researcher. "Not only does this suggest a molecular genetic link between these two neurodevelopmental disorders, it suggests that SHANK3 may have a role in other brain disorders."
SHANK3 is protein involved in maintaining the physical structure of nerve cells. Mutations in this gene result in specific abnormalities in cell shapes. These deformations have been observed in some schizophrenia patients, providing further evidence of the importance of the SHANK3 gene in this disorder.
These findings were made possible through the collaboration of several institutions such as the Harvard Medical School, McGill University and the Université Paris Descartes; please read on for complete list of funders and partners.
Affecting approximately one percent of the population, schizophrenia is a chronic psychiatric disorder characterized by disturbances in thinking, behaviour and emotion. Symptoms include delusions, hallucinations and withdrawal from social activity.
Partners in research:
This study was funded by Genome Canada, Génome Québec, the Université de Montréal and the Canada Foundation for Innovation.
About the study:
The article, "De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia," was coauthored by Julie Gauthier, Nathalie Champagne, Edna Brustein, Mathieu Lapointe, Huashan Peng, Marie-Pierre Dubé, Pierre Drapeau, Philip Awadalla and Guy Rouleau of the Université de Montréal, Fadi F. Hamdan and Mark E. Samuels of the Sainte-Justine University Hospital Research Center; Eric A. Stone of North Carolina State University; Philip A. Barker of the Montreal Neurological Institute; Anjené M. Addington and Judith L. Rapoport of the National Institute of Mental Health; Lynn E. DeLisi of the Harvard Medical School; Marie-Odile Krebs and Fayçal Mouaffak of the Université Paris Descartes; Ferid Fathalli, Ali P. Haghighi and Salvatore Carbonetto of McGill University / McGill University Health Centre; Ridha Joober of the Douglas Mental Health University Institute; Christian Néri of the Centre Paul Broca / INSERM.
Note to editors:
The Université de Montréal name can be adapted to University of Montreal (but never Montreal University).
On the Web:About the Proceedings of the National Academy of Sciences: www.pnas.org
Sylvain-Jacques Desjardins | EurekAlert!
When fat cells change their colour
28.10.2016 | Albert-Ludwigs-Universität Freiburg im Breisgau
Aquaculture: Clear Water Thanks to Cork
28.10.2016 | Technologie Lizenz-Büro (TLB) der Baden-Württembergischen Hochschulen GmbH
Physicists from the University of Würzburg have designed a light source that emits photon pairs. Two-photon sources are particularly well suited for tap-proof data encryption. The experiment's key ingredients: a semiconductor crystal and some sticky tape.
So-called monolayers are at the heart of the research activities. These "super materials" (as the prestigious science magazine "Nature" puts it) have been...
Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.
This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...
Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion
Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
28.10.2016 | Power and Electrical Engineering
28.10.2016 | Physics and Astronomy
28.10.2016 | Life Sciences